Long-term Outcome of Asymptomatic Esophageal Eosinophilia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Asymptomatic esophageal eosinophilia (aEE), characterized by eosinophil infiltration in the esophagus without clinical symptoms, has been reported as a precursor of eosinophilic esophagitis (EoE). Nevertheless, no report exists on the long-term clinical course of the disease. Therefore, this study aimed to investigate the long-term clinical course of aEE over 5 years, including the symptomatic conversion rate and the effect of treatments. Methods: We reviewed 28 patients with aEE who had been followed up for over 5 years with endoscopic monitoring. The basal characteristics of patients were compared with those of 58 patients diagnosed with EoE during the same period. Patients’ clinicopathological findings were collected and examined. Results: No significant differences in basal characteristics and histopathological findings were observed between the patients with aEE and those with EoE. The median follow-up duration was 64 months. Among the 28 patients with aEE, seven were treated with proton pump inhibitor or potassium-competitive acid blocker and the remaining 21 opted for follow-up with no medication. Among the treated patients, six (85.7%) exhibited endoscopic and pathologic improvements. Among the cases followed up without medication, the findings worsened in two (9.5%), improved spontaneously in seven (33.3%), and were unchanged in 12 (57.1%), and three (14.3%) developed symptoms at a mean time of 40 months. Symptoms developed in cases where endoscopic and pathologic findings remained unchanged or worsened during follow-up. Conclusions: Some patients with aEE had improved findings without treatment, whereas others developed symptoms, emphasizing the importance of long-term monitoring and individualized treatment decisions.
Abstract
Background/Aims: Asymptomatic esophageal eosinophilia (aEE), characterized by eosinophil infiltration in the esophagus without clinical symptoms, has been reported as a precursor of eosinophilic esophagitis (EoE). Nevertheless, no report exists on the long-term clinical course of the disease. Therefore, this study aimed to investigate the long-term clinical course of aEE over 5 years, including the symptomatic conversion rate and the effect of treatments. Methods: We reviewed 28 patients with aEE who had been followed up for over 5 years with endoscopic monitoring. The basal characteristics of patients were compared with those of 58 patients diagnosed with EoE during the same period. Patients’ clinicopathological findings were collected and examined. Results: No significant differences in basal characteristics and histopathological findings were observed between the patients with aEE and those with EoE. The median follow-up duration was 64 months. Among the 28 patients with aEE, seven were treated with proton pump inhibitor or potassium-competitive acid blocker and the remaining 21 opted for follow-up with no medication. Among the treated patients, six (85.7%) exhibited endoscopic and pathologic improvements. Among the cases followed up without medication, the findings worsened in two (9.5%), improved spontaneously in seven (33.3%), and were unchanged in 12 (57.1%), and three (14.3%) developed symptoms at a mean time of 40 months. Symptoms developed in cases where endoscopic and pathologic findings remained unchanged or worsened during follow-up. Conclusions: Some patients with aEE had improved findings without treatment, whereas others developed symptoms, emphasizing the importance of long-term monitoring and individualized treatment decisions.
참고문헌 (35)
- Straumann A, "Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response", J Allergy Clin Immunol, 108, pp.954~961 (2001)
- Navarro P, "Systematic review with metaanalysis : the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in populationbased studies", Aliment Pharmacol Ther, 49, pp.1116~1125 (2019)
- Arias Á, "Systematic review with meta-analysis : the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies", Aliment Pharmacol Ther, 43, pp.3~15 (2016)
- Dellon ES, "Prevalence of eosinophilic esophagitis in the United States", Clin Gastroenterol Hepatol, 12, pp.589~596 (2014)
- Ishimura N, "Eosinophilic esophagitis in Japan : focus on response to acid suppressive therapy", J Gastroenterol Hepatol, 33, pp.1016~1022 (2018)
- Dhar A, "British Society of Gastroenterology(BSG)and British Society of Paediatric Gastroenterology, Hepatology and Nutrition(BSPGHAN)joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults", Gut, 71, pp.1459~1487 (2022)
- Lucendo AJ, "Guidelines on eosinophilic esophagitis : evidence-based statements and recommendations for diagnosis and management in children and adults", United European Gastroenterol J, 5, pp.335~358 (2017)
- Dellon ES, "Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis : Proceedings of the AGREE Conference", Gastroenterology, 155, pp.1022~1033 (2018)
- Collins MH, "Eosinophilic esophagitis histology remission score : significant relations to measures of disease activity and symptoms", J Pediatr Gastroenterol Nutr, 70, pp.598~603 (2020)
- Safroneeva E, "Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis", Gastroenterology, 150, pp.581~590 (2016)
- Lucendo AJ, "Limitation of symptoms as predictors of remission in eosinophilic esophagitis : the need to go beyond endoscopy and histology", Gastroenterology, 150, pp.547~549 (2016)
- Kitamura H, "Eosinophilic esophagitis and asymptomatic esophageal eosinophilia display similar immunohistological profiles", J Clin Biochem Nutr, 68, pp.246~252 (2021)
- Ishimura N, "Is asymptomatic esophageal eosinophilia the same disease entity as eosinophilic esophagitis?", Clin Gastroenterol Hepatol, 17, pp.1405~1407 (2019)
- Suzuki Y, "Clinicopathological differences between eosinophilic esophagitis and asymptomatic esophageal eosinophilia", Intern Med, 61, pp.1319~1327 (2022)
- Hirano I, "Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis : validation of a novel classification and grading system", Gut, 62, pp.489~495 (2013)
- Dellon ES, "Accuracy of the eosinophilic esophagitis endoscopic reference score in diagnosis and determining response to treatment", Clin Gastroenterol Hepatol, 14, pp.31~39 (2016)
- Kon T, "Clinical features of esophageal eosinophilia according to endoscopic phenotypes", Intern Med, 59, pp.2971~2979 (2020)
- Armstrong D, "The endoscopic assessment of esophagitis : a progress report on observer agreement", Gastroenterology, 111, pp.85~92 (1996)
- Collins MH, "Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring", Dis Esophagus, 30, pp.1~8 (2017)
- Ishibashi F, "Risk of progression to eosinophilic esophagitis in patients with asymptomatic esophageal eosinophilia : a retrospective pilot study", JGH Open, 4, pp.422~428 (2019)
- Muroi K, "Subjective symptoms in patients with eosinophilic esophagitis are related to esophageal wall thickness and esophageal body pressure", Dig Dis Sci, 66, pp.2291~2300 (2021)
- Suzuki Y, "Mucosal and submucosal thickening of esophageal wall is a promising factor in the development of symptoms in eosinophilic esophagitis", Gut Liver, 18, pp.50~59 (2024)
- Kanamori A, "Esophageal mast cells may be associated with the perception of symptoms in patients with eosinophilic esophagitis", Esophagus, 20, pp.333~341 (2023)
- Dellon ES, "A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease", Gastrointest Endosc, 79, pp.577~585 (2014)
- Schreiner P, "How to approach adult patients with asymptomatic esophageal eosinophilia", Dis Esophagus, 34, pp.doaa105~ (2021)
- Fujiwara Y, "Symptom-based diagnostic approach for eosinophilic esophagitis", J Gastroenterol, 55, pp.833~845 (2020)
- Moosavi S, "Measuring esophageal compliance using functional lumen imaging probe to assess remodeling in eosinophilic esophagitis", Neurogastroenterol Motil, 35, pp.e14525~ (2023)
- Lucendo AJ, "Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 14, pp.13~22 (2016)
- Molina-Infante J, "Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults", Clin Gastroenterol Hepatol, 9, pp.110~117 (2011)
- Vazquez-Elizondo G, "The outcome of patients with oesophageal eosinophilic infiltration after an eightweek trial of a proton pump inhibitor", Aliment Pharmacol Ther, 38, pp.1312~1319 (2013)
- Ishimura N, "Sustained acid suppression by potassium-competitive acid blocker(P-CAB)may be an attractive treatment candidate for patients with eosinophilic esophagitis", Am J Gastroenterol, 111, pp.1203~1204 (2016)
- Dohil R, "Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis", Dig Dis Sci, 57, pp.1413~1419 (2012)
- Molina-Infante J, "Long-term loss of response in proton pump inhibitorresponsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis", Am J Gastroenterol, 110, pp.1567~1575 (2015)
- Ishimura N, "Similarity and difference in the characteristics of eosinophilic esophagitis between Western countries and Japan", Dig Endosc, 33, pp.708~719 (2021)
- Sato H, "Eosinophilic esophagitis in Japanese patients : a mild and slow-progressing disorder", PLoS One, 13, pp.e0206621~ (2018)